PMID- 32999909
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220417
IS  - 2341-4545 (Print)
IS  - 2387-1954 (Electronic)
IS  - 2387-1954 (Linking)
VI  - 27
IP  - 5
DP  - 2020 Aug
TI  - Azathioprine-Induced Acute Submandibular Sialadenitis in a Crohn's Disease 
      Patient.
PG  - 361-363
LID - 10.1159/000505037 [doi]
AB  - INTRODUCTION: Azathioprine (AZA) is a widely used immunosuppressive drug in 
      inflammatory bowel disease (IBD). The occurrence of adverse effects (AEs) is a 
      major downside in the use of this drug, leading to treatment withdrawal in a 
      variable proportion of patients. CASE PRESENTATION: We report the case of a 
      Crohn's disease patient who developed sialadenitis as an AE to AZA. DISCUSSION 
      AND CONCLUSION: To our knowledge this AE has been reported only once in the 
      literature. Sialadenitis is a common disorder and refers to inflammation of a 
      salivary gland. It has many causes, such as bacterial and viral infections, 
      ductal obstruction, and drugs. There are several AEs related to this drug, 
      categorized as dose-dependent and dose-independent. Their knowledge is essential 
      for therapeutic management in IBD, which is already challenging, requiring an 
      individualized approach.
CI  - Copyright (c) 2020 by S. Karger AG, Basel.
FAU - Alves da Silva, Joana Ines
AU  - Alves da Silva JI
AD  - Gastroenterology, Centro Hospitalar Universitario do Porto, Porto, Portugal.
FAU - Caetano, Cidalina
AU  - Caetano C
AD  - Gastroenterology, Centro Hospitalar Universitario do Porto, Porto, Portugal.
FAU - Pedroto, Isabel
AU  - Pedroto I
AD  - Gastroenterology, Centro Hospitalar Universitario do Porto, Porto, Portugal.
AD  - Instituto de Ciencias Biomedicas Abel Salazar, Porto, Portugal.
LA  - eng
PT  - Case Reports
DEP - 20200107
PL  - Switzerland
TA  - GE Port J Gastroenterol
JT  - GE Portuguese journal of gastroenterology
JID - 101685861
PMC - PMC7506223
OTO - NOTNLM
OT  - Adverse effect
OT  - Azathioprine
OT  - Crohn's disease
OT  - Sialadenitis
COIS- The authors have no conflicts of interest to declare.
EDAT- 2020/10/02 06:00
MHDA- 2020/10/02 06:01
PMCR- 2020/01/07
CRDT- 2020/10/01 05:38
PHST- 2019/07/24 00:00 [received]
PHST- 2019/11/12 00:00 [revised]
PHST- 2020/10/01 05:38 [entrez]
PHST- 2020/10/02 06:00 [pubmed]
PHST- 2020/10/02 06:01 [medline]
PHST- 2020/01/07 00:00 [pmc-release]
AID - pjg-0027-0361 [pii]
AID - 10.1159/000505037 [doi]
PST - ppublish
SO  - GE Port J Gastroenterol. 2020 Aug;27(5):361-363. doi: 10.1159/000505037. Epub 
      2020 Jan 7.